PMC:7463108 / 106191-106492 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T91 12-30 Chemical denotes protease inhibitor http://purl.obolibrary.org/obo/CHEBI_37670|http://purl.obolibrary.org/obo/CHEBI_60258
T93 21-30 Chemical denotes inhibitor http://purl.obolibrary.org/obo/CHEBI_35222
T84290 44-54 Chemical denotes atazanavir http://purl.obolibrary.org/obo/CHEBI_37924
T94858 55-64 Chemical denotes ritonavir http://purl.obolibrary.org/obo/CHEBI_45409
T64009 75-78 Chemical denotes CYP http://purl.obolibrary.org/obo/CHEBI_38559
T31065 149-162 Chemical denotes buprenorphine http://purl.obolibrary.org/obo/CHEBI_3216

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
3597 75-82 Gene denotes CYP 3A4 Gene:1576
3598 87-94 Gene denotes UGT 1A1 Gene:54658
3604 44-54 Chemical denotes atazanavir MESH:D000069446
3605 55-64 Chemical denotes ritonavir MESH:D019438
3606 149-162 Chemical denotes buprenorphine MESH:D002047
3607 167-183 Chemical denotes norbuprenorphine MESH:C043585

LitCovid-PD-GO-BP

Id Subject Object Predicate Lexical cue
T24 271-280 http://purl.obolibrary.org/obo/GO_0050890 denotes cognition

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T1335 0-301 Sentence denotes The boosted protease inhibitor combination, atazanavir/ritonavir, inhibits CYP 3A4 and UGT 1A1, leading to increases in overall systemic exposure of buprenorphine and norbuprenorphine and also results in symptoms of opioid excess, such as increased sedation and impaired cognition (McCance-Katz et al.